Latest News

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

February 5th 2025

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

Top 10 kidney stone stories in 2024
Top 10 kidney stone stories in 2024

December 25th 2024

Published ASPIRE data show noninferior stone-free rate with SURE vs URS
Published ASPIRE data show noninferior stone-free rate with SURE vs URS

December 23rd 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1
FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

December 19th 2024

FDA grants de novo clearance to Stone Clear device
FDA grants de novo clearance to Stone Clear device

November 13th 2024

More News

© 2025 MJH Life Sciences

All rights reserved.